---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-037679"
form_type: "8-K"
ticker: "QCLS"
cik: "0001321834"
company_name: "Q/C TECHNOLOGIES, INC."
filed_at: "2023-10-19T23:59:59+00:00"
generated_at: "2026-06-09T19:54:08.981291+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# MyMD Supera-CBD preclinical study shows rapid pain relief; Japanese patent granted

## Summary
- Supera-CBD reduced acute inflammatory heat pain within 60 minutes; relief lasted up to five hours; traditional CBD had no effect.
- Study at major academic center suggests Supera-CBD targets TRPV1 channels, potentially fewer side effects than opioids.
- DEA determined Supera-CBD is not a controlled substance under the CSA; no scheduling required during development.
- Japanese Patent No. 7293561 B2 issued for Supera-CBD as new molecular entity; company now holds 23 issued patents worldwide.

## SEC filing metadata
- accession: 0001493152-23-037679
- form_type: 8-K
- ticker: QCLS
- cik: 0001321834
- company_name: Q/C TECHNOLOGIES, INC.
- filed_at: 2023-10-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1321834/000149315223037679/0001493152-23-037679-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1321834/000149315223037679/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-037679
- JSON: https://secwatch.observer/filing/0001493152-23-037679.json
- Plain text: https://secwatch.observer/filing/0001493152-23-037679.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.